Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2024 11:07 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
January 26, 2021 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
November 10, 2020 01:08 ET | Source: Immunophotonics, Inc.

Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors

ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
October 23, 2020 01:00 ET | Source: INNATE PHARMA

L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca

Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
October 23, 2020 01:00 ET | Source: INNATE PHARMA

First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
July 15, 2020 08:05 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
May 27, 2020 07:00 ET | Source: Amunix Pharmaceuticals, Inc.

Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality

MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
May 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma présente de nouvelles données d'efficacité pour monalizumab en combinaison avec cetuximab dans les cancers de la tête et du cou lors de congrès virtuel de l'ASCO20

Dans l’expansion de cohorte (Phase II), un taux de réponse globale de 20% a été observé chez des patients précédemment traités par une immunothérapie anti-PD-(L)1 Ces données confirment les...
May 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20 Virtual Scientific Progral

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext...
May 14, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation MARSEILLE, France,...

Next Page keyboard_arrow_right